Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
23 July 2021Website:
http://cytekbio.comNext earnings report:
07 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | 24 min agoDividend
Analysts recommendations
Institutional Ownership
CTKB Latest News
FREMONT, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that its Chief Operating Officer, Chris Williams, will resign his position effective September 27, 2024, to accept a CEO position at another company. Cytek has chosen not to replace the COO position, opting instead to restructure the organization to create a flatter, more efficient management structure.
Cytek Biosciences, Inc. (NASDAQ:CTKB ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Paul Goodson - Investor Relations Wenbin Jiang - Chief Executive Officer William McCombe - Chief Financial Officer Conference Call Participants Operator Thank you for standing by. My name is Luella, and I will be your conference operator today.
Cytek has developed a revolutionary tool to automate panel design. SpectroPanel is an intelligent algorithm that suggests optimized panels in minutes.
FREMONT, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Today Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, officially announced its Enhanced Small Particle (ESP™) Detection Option for its flagship Cytek Aurora™ and Cytek Northern Lights™ cell analysis systems.
Cytek Biosciences, Inc. (Nasdaq: CTKB), a prominent company in cell analysis solutions, is dedicated to advancing the cell analysis market through participation in important industry events globally.
Investors frequently consider the advice of Wall Street analysts before making decisions on whether to buy, sell, or hold a stock. Changes in ratings by these analysts, who are employed by brokerage firms, can impact the price of a stock based on media reports.
The intense selling pressure on Cytek Biosciences (CTKB) appears to have eased as it is now considered oversold from a technical standpoint. Furthermore, the consensus among Wall Street analysts in raising earnings forecasts suggests that the stock may be poised for a turnaround.
The average price target suggests a potential 47.6% increase for Cytek Biosciences (CTKB). Although studies show this metric may not always be accurate, a rise in earnings forecasts could indicate a positive outlook for the stock in the short term.
Cytek Biosciences is a leading cellular analysis instrument maker with a focus on the Aurora flow cytometry platform. Despite a downturn in the healthcare market, Cytek has maintained revenue growth above 15% since IPO. Cytek's technological advantage, broadening ecosystem, and potential in the clinical and biopharma space contribute to the leading financials and positive outlook.
Cytek Biosciences, Inc. (CTKB) Q4 2023 Earnings Call Transcript
- 1(current)
What type of business is Cytek Biosciences?
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
What sector is Cytek Biosciences in?
Cytek Biosciences is in the Healthcare sector
What industry is Cytek Biosciences in?
Cytek Biosciences is in the Medical Devices industry
What country is Cytek Biosciences from?
Cytek Biosciences is headquartered in United States
When did Cytek Biosciences go public?
Cytek Biosciences initial public offering (IPO) was on 23 July 2021
What is Cytek Biosciences website?
https://cytekbio.com
Is Cytek Biosciences in the S&P 500?
No, Cytek Biosciences is not included in the S&P 500 index
Is Cytek Biosciences in the NASDAQ 100?
No, Cytek Biosciences is not included in the NASDAQ 100 index
Is Cytek Biosciences in the Dow Jones?
No, Cytek Biosciences is not included in the Dow Jones index
When was Cytek Biosciences the previous earnings report?
No data
When does Cytek Biosciences earnings report?
The next expected earnings date for Cytek Biosciences is 07 November 2024